Lupin Limited, an internationally recognized pharmaceutical company, has announced the release of its FDA-approved bumetanide injection USP in the United States. Available in two forms, the medication comes in 1 mg/4 mL (0.25 mg/mL) single-dose vials and 2.5 mg/10 mL (0.25 mg/mL) multi-dose vials.
This bumetanide injection USP serves as a generic version of Bumex injection at 0.25 mg/mL, originally by Validus Pharmaceuticals, LLC. It is prescribed for managing edema linked to conditions such as congestive heart failure, hepatic and renal diseases, including the nephrotic syndrome.
According to IQVIA MAT data from September 2024, this generic bumetanide injection (reference listed drug Bumex) boasts an estimated annual revenue of $20 million in the United States.
Headquartered in Mumbai, India, Lupin Limited stands as a global leader in the pharmaceutical industry. Lupin’s extensive product range is distributed across more than 100 markets, focusing on both branded and generic formulations, intricate generics, biotechnology items, and active pharmaceutical ingredients.